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Vaccination is critical for the prevention and control of infectious-disease outbreaks, being of paramount
importance to global health, they are a key component of primary health care and an indisputable human right.
Yet far too many people around the world have insufficient access to vaccines. The limited availability and
affordability of vaccines to resource low-income countries has created a need for solutions that will ensure
effective, affordable vaccine production technology. With potential for more pandemics, the urgency to expand
vaccine range has become even more evident.
We will present a collaborative project between UCL and PT Bio Farma in which we have developed platforms
to manufacture two novel immunization candidates, a recombinant virus-like-particles vaccine against Dengue
disease (case study 1) and a recombinant protein vaccine against COVID-19 disease (case study 2). Both
vaccines will have a social and economic impact by reducing the number of cases, and the overall mortality and
morbidity.
Dengue is an emerging mosquito-borne viral infection with increasing reports of outbreaks and can be in tropical
and sub-tropical areas, with Southeast Asia and the Western Pacific being the most seriously affected zones. A
total of 3.8 billion people is potentially at risk, and in a scenario of global warming, this can increase to 6 billion
people by 2080. To date, there is one commercialized vaccine (Sanofi-Pasteur) but is restricted to individuals
aging from 9-45 years, who have been previously infected with the virus. The COVID-19 pandemic has sum
approx. 400 million cases and 6 million deaths worldwide since it was first reported in 2019. Even though the
production and delivery of a vaccine has significantly increased over time, the affordability, accessibility, and
acceptability at individual and country levels is still a major limitation.
The work performed consisted in the establishment of a cost-effective manufacturing processes to be
implemented in Indonesia, which is classified as a lower-middle income country (World Bank 2021). Pichia
pastoris (Komagataella phaffii) was used as a host in both vaccine manufacturing processes, since it is one of
the most promising candidates for expression of heterologous proteins in vaccines development. It combines
the speed and ease of highly efficient prokaryotic platforms with some key capabilities of mammalian systems.
We have increased production yields, by employing scale down methodologies, and scaled-up production of the
COVID-19 vaccine at the partner company. To ensure high product quality, we have simplified vaccine
purification using affinity chromatography and developed alternative biophysical characterisation methods for
the dengue vaccine prototype.
We have successfully demonstrated the versatility of using K. phaffii platform in the manufacturing of soluble
vaccines (S1 SARS-CoV-2 RBD antigen) as well as the production of nanoparticles (dengue virus like particles,
VLPS). Overall, these two case studies, will act as a foundation for the establishment and development of
COVID-19 and dengue vaccine for industrial production, enabling Indonesia to be self-sufficient in a pandemic
situation.
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